Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a second major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, effective immediately. The agreement adds approximately 21 million Medicare lives, bringing total Medicare coverage to approximately 32 million lives, or 58% of approximately 55 million Medicare lives in the U.S. This expanded coverage is significant because it makes the first new fibromyalgia treatment in more than 15 years accessible to a majority of Medicare beneficiaries, potentially improving care for a condition that affects millions of Americans.
According to Tonix Pharmaceuticals (NASDAQ: TNXP), total commercial and government payer coverage for TONMYA® now reaches approximately 166 million covered lives, or 53% of approximately 314 million total U.S. lives. The company also said approximately 50 new sales representatives have been fully activated in the field, bringing its total sales force to 150 representatives. This expanded sales force is expected to drive awareness and adoption of TONMYA® among healthcare providers.
The company previously announced commercial payer agreements with two leading group purchasing organizations and one major managed Medicare agreement, while TONMYA® is also covered by Medicaid in nearly all states. To view the full press release, visit https://ibn.fm/Q8TKY. These developments underscore Tonix’s commitment to ensuring broad access to its flagship medicine.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Investors seeking the latest news and updates relating to TNXP can visit the company’s newsroom at https://ibn.fm/TNXP. The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication, including editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. For full terms of use and disclaimers, see https://www.InvestorWire.com/Disclaimer.
